<DOC>
	<DOCNO>NCT02961764</DOCNO>
	<brief_summary>This study evaluate new critical pathway ( use guideline-based patient identification criterion meet criterion , use dalbavancin ) treatment ABSSSI compare usual care .</brief_summary>
	<brief_title>Evaluation New Critical Pathway Treatment Acute Bacterial Skin Skin Structure Infections ( ABSSSI )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<criteria>Presents Emergency Department ( ED ) meet clinical definition Acute Bacterial Skin Skin Structure Infections ( ABSSSI ) Known suspect grampositive infection . Known suspected gramnegative infection , anaerobic infection , fungemia Known suspect infection severe , life threaten include ABSSSI Food Drug Administration ( FDA ) guidance Injection drug user fever Severe neurological disorder lead immobility confine wheelchair Bilateral Lower extremity involvement suspect infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Critical Pathways</keyword>
	<keyword>Health Facilities</keyword>
	<keyword>Clinical Protocols</keyword>
	<keyword>Patient Satisfaction</keyword>
	<keyword>Absenteeism</keyword>
	<keyword>Anti-Bacterial Agents</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Economics , Medical</keyword>
	<keyword>Health Resources</keyword>
	<keyword>Health resource utilization</keyword>
	<keyword>Acute bacterial skin skin structure infection ( ABSSSI )</keyword>
</DOC>